Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574327 · ClinicalTrials.gov registry record
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
A clinical trial of Esophageal Adenocarcinoma and Gastroesophageal Reflux Disease, sponsored by Midwest Biomedical Research Foundation.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT00574327: Recruiting study of Esophageal Adenocarcinoma and Gastroesophageal Reflux Disease, sponsored by Midwest Biomedical Research Foundation.
NCT00574327 is a study of Esophageal Adenocarcinoma and Gastroesophageal Reflux Disease that is actively recruiting participants, run by Midwest Biomedical Research Foundation. The registered enrollment target is 3,000 participants, above the 239-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (1155% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00574327, a study of Esophageal Adenocarcinoma and Gastroesophageal Reflux Disease, is actively recruiting participants, sponsored by Midwest Biomedical Research Foundation.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine or evaluate the risk factors such as smoking, family history etc. that cause esophageal cancer and to determine the genetic changes that lead to esophageal cancer. The investigators hypothesis is that systematic collection of data on the natural history of GERD and BE patients and risk factors for development of BE in patients with chronic GERD and progression of BE to dysplasia and adenocarcinoma will provide useful information to develop a decision model for risk stratification and risk reduction strategies in these patients. As of March 17, 2011, 585 patients have consented at the Kansas City VA Medical Center.
Conditions Studied
Study Locations (1)
Missouri
- Department of Veterans Affairs Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2006-01 |
| Est. Completion | 2029-01 |
What NCT00574327 shows while recruiting
NCT00574327 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 239-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (1155% higher).
The record links to 3 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT00574327 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00574327 about?
NCT00574327 is a clinical study titled "Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry". The purpose of this study is to determine or evaluate the risk factors such as smoking, family history etc. that cause esophageal cancer and to determine the genetic changes that lead to esophageal cancer. The investigators hypothesis is that systematic collection of data on the natural history of G...
What is the current status of trial NCT00574327?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2006-01. Estimated completion is 2029-01.
What conditions does trial NCT00574327 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Gastroesophageal Reflux Disease, Barrett's Esophagus.
Who is sponsoring clinical trial NCT00574327?
This trial is sponsored by Midwest Biomedical Research Foundation, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00574327 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00574327's enrollment target sits among peer trials
3,000 1st of 43 higher than 43 of 43 other Esophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia